12/11/2024
Dose Escalation Approved and Dosing Commenced in Second Cohort of GPN Vaccines’ Phase 1 Clinical Trial in Older Adults
Adelaide, Australia, 12 th November 2024 – GPN Vaccines Ltd is pleased to announce that dose escalation has…
Clinical Trials
Financial Statements
Read article
04/09/2024First Participant Dosed in Phase 1 Clinical Trial of Gamma-PN in Older Adults
Read articleAdelaide, Australia, 5th September 2024 – GPN Vaccines Ltd is pleased to announce that the first participant has…
21/08/2024GPN Vaccines Secures Ethics Approval for a Clinical Trial of its Pneumococcal Vaccine in Older Adults
Read articleAdelaide, Australia, 21st August 2024 GPN Vaccines is pleased to announce it has received ethics approval to commence…
- 03/01/2024
Positive Safety and Immunogenicity Data from Phase 1 Trial of Gamma-PN
Read articleAdelaide, Australia GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia…
- 07/08/2023
GPN Vaccines Reaches 100% Recruitment in Phase I Clinical Trial
Read articleAdelaide, Australia, 7th August 2023 GPN Vaccines is pleased to announce that the Phase I clinical trial of…
- 22/06/2023
Dosing Commenced Cohort 3 of GPN Vaccines’ Phase 1 Clinical Trial
Read articleAdelaide, Australia- 22nd June 2023 – GPN Vaccines Ltd is pleased to announce dose escalation has been approved…
- 30/03/2023
Dosing Commenced in Cohort 2 of GPN Vaccines’ Phase 1 Clinical Trial
Read articleAdelaide, Australia, 30th March 2023 – GPN Vaccines Ltd is pleased to announce that dose escalation has been approved…
- 16/01/2023
First Participant Dosed in Phase 1 Clinical Trial of Gamma-PN
Read articleAdelaide, Australia, 16th January 2023 GPN Vaccines Ltd is pleased to announce that the first participant has been…
